Follow this preprint
Relapse prediction in multiple myeloma patients treated with isatuximab, carfilzomib, and dexamethasone
View ORCID ProfileEven Moa Myklebust, View ORCID ProfileFredrik Schjesvold, View ORCID ProfileArnoldo Frigessi, View ORCID ProfileKevin Leder, View ORCID ProfileJasmine Foo, View ORCID ProfileAlvaro Köhn-Luque
doi: https://doi.org/10.1101/2024.05.02.24306607
This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.
Even Moa Myklebust
1Oslo Centre for Biostatistics and Epidemiology, Faculty of Medicine, University of Oslo, 0372 Oslo, Norway
Fredrik Schjesvold
2KG Jebsen Center for B-Cell Malignancies, Institute for Clinical Medicine, University of Oslo, 0450 Oslo, Norway
3Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, 0450 Oslo, Norway
Arnoldo Frigessi
1Oslo Centre for Biostatistics and Epidemiology, Faculty of Medicine, University of Oslo, 0372 Oslo, Norway
Kevin Leder
4College of Science and Engineering, University of Minnesota, Minneapolis, MN 55455, USA
Jasmine Foo
5Institute for Mathematics and its Applications, School of Mathematics, University of Minnesota, Minneapolis, MN 55455, USA
Alvaro Köhn-Luque
1Oslo Centre for Biostatistics and Epidemiology, Faculty of Medicine, University of Oslo, 0372 Oslo, Norway
6Oslo Centre for Biostatistics and Epidemiology, Oslo University Hospital, 0372 Oslo, Norway

Posted May 06, 2024.
Relapse prediction in multiple myeloma patients treated with isatuximab, carfilzomib, and dexamethasone
Even Moa Myklebust, Fredrik Schjesvold, Arnoldo Frigessi, Kevin Leder, Jasmine Foo, Alvaro Köhn-Luque
medRxiv 2024.05.02.24306607; doi: https://doi.org/10.1101/2024.05.02.24306607
This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
1
Blogs/Media
0
Author Videos
Subject Areas
- Addiction Medicine (410)
- Allergy and Immunology (722)
- Anesthesia (214)
- Cardiovascular Medicine (3067)
- Dermatology (259)
- Emergency Medicine (460)
- Epidemiology (12996)
- Forensic Medicine (13)
- Gastroenterology (857)
- Genetic and Genomic Medicine (4806)
- Geriatric Medicine (443)
- Health Economics (749)
- Health Informatics (3043)
- Health Policy (1100)
- Hematology (406)
- HIV/AIDS (954)
- Medical Education (453)
- Medical Ethics (119)
- Nephrology (497)
- Neurology (4582)
- Nursing (243)
- Nutrition (680)
- Oncology (2377)
- Ophthalmology (671)
- Orthopedics (267)
- Otolaryngology (332)
- Pain Medicine (299)
- Palliative Medicine (87)
- Pathology (514)
- Pediatrics (1235)
- Primary Care Research (516)
- Public and Global Health (7161)
- Radiology and Imaging (1592)
- Respiratory Medicine (941)
- Rheumatology (458)
- Sports Medicine (400)
- Surgery (507)
- Toxicology (64)
- Transplantation (218)
- Urology (188)